Showing 1 – 2 of 2
Relevance | Newest | Oldest |
  • JAMA Cardiology Original Investigation
    April 17, 2024

    Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial

    Yi听Li,听MD; Jing听Li,听MD; Bin听Wang,听MD; Quanmin听Jing,听MD; Yujie听Zeng,听MD; Aijie听Hou,听MD; Zhifang听Wang,听MD; Aijun听Liu,听MD; Jinliang听Zhang,听MD; Yaojun听Zhang,听MD; Ping听Zhang,听MD; Daming听Jiang,听MD; Bin听Liu,听MD; Jiamao听Fan,听MD; Jun听Zhang,听MD; Li听Li,听MD; Guohai听Su,听MD; Ming听Yang,听MD; Weihong听Jiang,听MD; Peng听Qu,听MD; Hesong听Zeng,听MD, PhD; Lu听Li,听MD; Miaohan听Qiu,听MD; Leisheng听Ru,听MD; Shaoliang听Chen,听MD; Yujie听Zhou,听MD; Shubin听Qiao,听MD; Gregg W.听Stone,听MD; Dominick J.听Angiolillo,听MD, PhD; Yaling听Han,听MD; OPT-BIRISK Investigators
    Abstract Full Text
    online first
    JAMA Cardiol. 2024; 10.1001/jamacardio.2024.0534

    This randomized clinical trial evaluates clopidogrel monotherapy vs dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions who are at high bleeding and ischemic risk.

  • 榴莲视频 Network Open Original Investigation Cardiology
    February 10, 2023

    Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial

    Shenghua听Zhou,听MD; Yichao听Xiao,听MD; Chonglun听Zhou,听MD; Zhaofen听Zheng,听MD; Weihong听Jiang,听MD; Qiang听Shen,听MD; Can听Zhu,听MD; Hongwei听Pan,听MD; Changhui听Liu,听MD; Gaofeng听Zeng,听MD; Liangqing听Ge,听MD; Yumin听Zhang,听MD; Zewei听Ouyang,听MD; Guang听Fu,听MD; Gang听Pan,听MD; Feng听Chen,听MD; Lihong听Huang,听MD; Qiming听Liu,听MD; H-REPLACE Investigators
    Abstract Full Text
    open access
    榴莲视频 Netw Open. 2023; 6(2):e2255709. 10.1001/jamanetworkopen.2022.55709

    This randomized equivalence and noninferiority trial compares safety and efficacy of enoxaparin vs rivaroxaban 2.5 or 5 mg for patients with acute coronary syndrome (ACS) in the acute phase.